

Appl. No. 09/529,575
Amdt. Dated Sept. 8, 2003
Reply to Office Action of May 6, 2003

AMENDMENTS TO THE CLAIMS

Please amend Claims as follows:

- 1-30. (canceled)
31. (currently amended) An absorbent article at least a portion of which comprises a protease inhibitor, wherein the ~~protease inhibitor article~~ article comprises from about ~~0.001%~~ 0.0001% to about 30%₂ by weight₁ of the ~~article~~ protease inhibitor; the protease inhibitor has an IC₅₀ of about 500 μM or less, as measured by a General Fecal Protease Method; and the protease inhibitor is selected from the group consisting of 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride, hexamidine and its salts, pentamidine and its salts, and mixtures thereof.
32. (original) The article of claim 31 wherein the IC₅₀ is no more than 100 μM.
33. (original) The article of claim 31 wherein an extract of at least a portion of the article produces at least a 10% reduction in substrate hydrolysis by a protease in an Absorbent Article Test Method.
- 34-35. (canceled)
36. (currently amended) An absorbent article at least a portion of which comprises a protease inhibitor, wherein the ~~protease inhibitor article~~ article comprises from about ~~0.001%~~ 0.0001% to about 30%₂ by weight₁ of the ~~article~~ protease inhibitor; an extract of at least a portion of the absorbent article produces a 20% reduction in substrate hydrolysis by a protease in an Absorbent Article Test Method; and the protease inhibitor is selected from the group consisting of 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride, hexamidine and its salts, pentamidine and its salts, and mixtures thereof.
- 37-40. (canceled)
41. (previously presented) The article of claim 31, wherein the absorbent article comprises a delivery system and the delivery system contains the protease inhibitor.
42. (previously presented) The article of claim 41, wherein the delivery system is a skin care composition and the ~~protease inhibitor skin care composition~~ skin care composition comprises from about 0.01% to about 50%₂ by weight₁ of the ~~skin care composition~~ protease inhibitor.
43. (original) The article of claim 42, wherein the skin care composition is transferable to the skin of a wearer.

Appl. No. 09/529,575

Amdt. Dated Sept. 8, 2003

Reply to Office Action of May 6, 2003

44. (original) The article of claim 41, wherein the delivery system comprises a microcapsule, an absorbent material, a cell, an adhesive, a skin care composition, a nanophase particulate structure, a solid support, or combinations thereof.
45. (original) The article of claim 41, wherein the delivery system is activatable by moisture, heat, or pressure, or combination thereof, and wherein the delivery system releases the protease inhibitor when activated.
46. (original) The article of claim 41, wherein the delivery system contains the protease inhibitor as a powder, a flake, a particle, a solution, a suspension, a dispersion, an emulsion, or combination thereof.
47. (canceled)
48. (original) The article of claim 31, wherein the absorbent article comprises a wearer-contacting surface having the protease inhibitor disposed on at least a portion thereof.
49. (original) The article of claim 48, wherein the wearer-contacting surface is a topsheet, a leg cuff, a side panel, or a waist region.
50. (original) The article of claim 49, wherein a skin care composition containing the protease inhibitor is disposed on at least a portion of the wearer-contacting surface.
51. (original) The article of claim 50, wherein the wearer-contacting surface is the topsheet.
52. (original) The article of claim 51, wherein the topsheet comprises one or more regions that do not contain the skin care composition.
53. (previously presented) The article of claim 51, wherein the skin care composition is disposed on the topsheet in a plurality of stripes.